Trial Profile
A Phase 1/2, Randomized Clinical Study to Assess the Safety and Efficacy of Sirolimus in Patients With Newly Diagnosed, Treatment-Naive Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 19 May 2014
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Age-related macular degeneration; Choroidal neovascularisation
- Focus Therapeutic Use
- Sponsors Santen Pharmaceutical
- 19 May 2014 New trial record